Subsequent anti -cancer therapy will also be collected during off -treatment fol low up and survival follow up. Any concomitant medication(s), including herbal or vitamin preparations, taken during the study will be recorded in the CRF. At a minimum, the drug name, dose, and the dates of administration will be recorded. 11.3. Permitted Medi cations Local and/or systemic injection reactions may be treated with anti histamines , antipyretics, and/or analgesics in accordance with standard local practice and Investigator ’s clinical judgment. Pre-treatment of the vaccine injection site with anesthet ic cream is allowed only after the Week 1 vaccine administration has been performed without it , and injection pain has been documented as an AE. Prohibited Medications In principle, steroid therapy is not permitted, but use of steroids for TEAEs may be considered after consultation with the Medical Monitor. Patients receiving replacement doses of corticosteroids for adrenal insufficiency should not have their replacement dose withheld. Arm 6 patients receiving SOC pemetrexed may receive steroids as recommended per Package Insert. Heat Biologics, Inc. Viagenpumatucel -L Protocol HS110 -102 CONFIDENTIAL Amendment 6, 24 May 2019 Page 56 of 95 Topical and inhal ed steroids will be permitted. Other than protocol -defined agents, n o concomitant chemotherapy, immunotherapy, immunosuppressive or other anticancer therapy will be permitted while receiving study treatme nts. Administration of other concomitant investigational agents, for any indication, is not permitted while on this study. During survival follow -up there are no prohibited medications, and patients may enroll in any investigational study for which they ar e eligible. Supportive Care Patients should receive full supportive care during the study, including transfusions of blood and blood products; treatment with antibiotics, antiemetics, antidiarrheals, and analgesics; and other care as deemed appropriate and in accordance with their institutional guidelines. 11.4. Treatment of Investigational Product Overdose There have been no cases o f overdose with HS-110. Treatment of any suspected or confirme d overdose with HS-110 should be symptomatic, and supportive care is r ecommended in cases where overdose is suspected. As described in the Investigator’s Brochure (IB) for HS-110, the Sponsor does not recommend specific treatment for overdose or toxicity; however, the Investigator should use appropriate clinical judgment in treating the overdose. For the purposes of this study, an overdose of HS-110 is defined as any dose 50% greater than the intended dose for that patient. Appropriate supportive care measures may need to be provided to address these potential toxicities in the event of an overdose.